177 related articles for article (PubMed ID: 23006531)
1. Hepatitis C virus infection and related risk factors among injection drug users in Montenegro.
Baćak V; Laušević D; Mugoša B; Vratnica Z; Terzić N
Eur Addict Res; 2013; 19(2):68-73. PubMed ID: 23006531
[TBL] [Abstract][Full Text] [Related]
2. Risk behaviors and antibody hepatitis B and C prevalence among injecting drug users in south-western Sydney, Australia.
Maher L; Chant K; Jalaludin B; Sargent P
J Gastroenterol Hepatol; 2004 Oct; 19(10):1114-20. PubMed ID: 15377287
[TBL] [Abstract][Full Text] [Related]
3. Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales.
Sutton AJ; Gay NJ; Edmunds WJ; Hope VD; Gill ON; Hickman M
BMC Infect Dis; 2006 Jun; 6():93. PubMed ID: 16762050
[TBL] [Abstract][Full Text] [Related]
4. Population-based prevalence of hepatitis B and C virus, HIV, syphilis, gonorrhoea and chlamydia in male injection drug users in Lagos, Nigeria.
Tun W; Vu L; Adebajo SB; Abiodun L; Sheehy M; Karlyn A; Njab J; Ahonsi B; Issa BK; Idogho O
Int J STD AIDS; 2013 Aug; 24(8):619-25. PubMed ID: 23970571
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C, B, and human immunodeficiency virus infections in illicit drug users in Israel: prevalence and risk factors.
Loebstein R; Mahagna R; Maor Y; Kurnik D; Elbaz E; Halkin H; Olchovsky D; Ezra D; Almog S
Isr Med Assoc J; 2008 Nov; 10(11):775-8. PubMed ID: 19070285
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and associated clinical characteristics of hepatitis B, C, and HIV infections among injecting drug users in Korea.
Min JA; Yoon Y; Lee HJ; Choi J; Kwon M; Kim K; Lee CU; Kim DJ; Yun H
J Med Virol; 2013 Apr; 85(4):575-82. PubMed ID: 23364858
[TBL] [Abstract][Full Text] [Related]
7. Improving survey methods in sero-epidemiological studies of injecting drug users: a case example of two cross sectional surveys in Serbia and Montenegro.
Judd A; Rhodes T; Johnston LG; Platt L; Andjelkovic V; Simić D; Mugosa B; Simić M; Zerjav S; Parry RP; Parry JV
BMC Infect Dis; 2009 Feb; 9():14. PubMed ID: 19203380
[TBL] [Abstract][Full Text] [Related]
8. High HIV and hepatitis C prevalence amongst injecting drug users in Mauritius: findings from a population size estimation and respondent driven sampling survey.
Johnston L; Saumtally A; Corceal S; Mahadoo I; Oodally F
Int J Drug Policy; 2011 Jul; 22(4):252-8. PubMed ID: 21700442
[TBL] [Abstract][Full Text] [Related]
9. Markers and risk factors for HCV, HBV and HIV in a network of injecting drug users in Melbourne, Australia.
Miller ER; Hellard ME; Bowden S; Bharadwaj M; Aitken CK
J Infect; 2009 May; 58(5):375-82. PubMed ID: 19328555
[TBL] [Abstract][Full Text] [Related]
10. Co-infection by human immuno deficiency virus, hepatitis B and hepatitis C virus in injecting drug users.
Devi KhS; Brajachand N; Singh HL; Singh YM
J Commun Dis; 2005 Mar; 37(1):73-7. PubMed ID: 16637404
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus infection, HIV co-infection, and associated risk among injecting drug users in Togliatti, Russia.
Rhodes T; Platt L; Judd A; Mikhailova LA; Sarang A; Wallis N; Alpatova T; Hickman M; Parry JV
Int J STD AIDS; 2005 Nov; 16(11):749-54. PubMed ID: 16303071
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C infection among intravenous drug users attending therapy programs in Cyprus.
Demetriou VL; van de Vijver DA; Hezka J; Kostrikis LG; ; Kostrikis LG
J Med Virol; 2010 Feb; 82(2):263-70. PubMed ID: 20029809
[TBL] [Abstract][Full Text] [Related]
13. Frontloading: a risk factor for HIV and hepatitis C virus infection among injecting drug users in Berlin.
Stark K; Müller R; Bienzle U; Guggenmoos-Holzmann I
AIDS; 1996 Mar; 10(3):311-7. PubMed ID: 8882671
[TBL] [Abstract][Full Text] [Related]
14. Molecular epidemiology of HCV monoinfection and HIV/HCV coinfection in injection drug users in Liuzhou, Southern China.
Tan Y; Wei QH; Chen LJ; Chan PC; Lai WS; He ML; Kung HF; Lee SS
PLoS One; 2008; 3(10):e3608. PubMed ID: 18974888
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of, and risk factors for, hepatitis C virus infection among recent initiates to injecting in London and Glasgow: cross sectional analysis.
Judd A; Hutchinson S; Wadd S; Hickman M; Taylor A; Jones S; Parry JV; Cameron S; Rhodes T; Ahmed S; Bird S; Fox R; Renton A; Stimson GV; Goldberg D
J Viral Hepat; 2005 Nov; 12(6):655-62. PubMed ID: 16255768
[TBL] [Abstract][Full Text] [Related]
16. Demographic, risk behaviour and personal network variables associated with prevalent hepatitis C, hepatitis B, and HIV infection in injection drug users in Winnipeg, Canada.
Wylie JL; Shah L; Jolly AM
BMC Public Health; 2006 Sep; 6():229. PubMed ID: 16970811
[TBL] [Abstract][Full Text] [Related]
17. HIV, hepatitis C virus, and hepatitis B virus co-infections among injecting drug users in Tehran, Iran.
Rahimi-Movaghar A; Razaghi EM; Sahimi-Izadian E; Amin-Esmaeili M
Int J Infect Dis; 2010 Jan; 14(1):e28-33. PubMed ID: 19464218
[TBL] [Abstract][Full Text] [Related]
18. Coinfection with HIV and hepatitis C virus among injection drug users in southern China.
Garten RJ; Zhang J; Lai S; Liu W; Chen J; Yu XF
Clin Infect Dis; 2005 Jul; 41 Suppl 1():S18-24. PubMed ID: 16265609
[TBL] [Abstract][Full Text] [Related]
19. An urgent need to scale-up injecting drug harm reduction services in Tanzania: prevalence of blood-borne viruses among drug users in Temeke District, Dar-es-Salaam, 2011.
Bowring AL; Luhmann N; Pont S; Debaulieu C; Derozier S; Asouab F; Toufik A; van Gemert C; Dietze P; Stoove M
Int J Drug Policy; 2013 Jan; 24(1):78-81. PubMed ID: 23036650
[TBL] [Abstract][Full Text] [Related]
20. Extremely high prevalence and genetic diversity of hepatitis C virus infection among HIV-infected injection drug users in Taiwan.
Liu JY; Lin HH; Liu YC; Lee SS; Chen YL; Hung CC; Ko WC; Huang CK; Lai CH; Chen YS; Shih YL; Chung HC; Liang SH; Lin JN
Clin Infect Dis; 2008 Jun; 46(11):1761-8. PubMed ID: 18433337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
